Uric Acid and Diabetic Nephropathy Risk.
Uric Acid and Diabetic Nephropathy Risk.
复制标题
DOI：
10.1159/000484284
复制
发表时间：
2018
影响因子：
--
通讯作者：
Doria A
中科院分区：
文献类型：
--
作者：
Mauer M;Doria A
糖尿病肾病（DKD）是西方世界终末期肾病（ESKD）的主要原因。更好地控制血压和血压，包括肾素-血管紧张素系统阻断（RASB），似乎已经减缓了DKD的进展速度，但无法显著降低DKD相关ESKD新发病例的年发生率。因此，需要新的治疗目标。血清尿酸（SUA）水平升高与1型（T1 D）和2型（T2 D）糖尿病患者以及一般慢性肾病（CKD）患者的DKD风险和进展增加相关。本文综述了流行病学、临床和临床试验证据，这些证据表明SUA减少可以减缓DKD和/或CKD的进展。
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) in the Western world. Better control of glycemia and blood pressure, including renin-angiotensin system blockade (RASB), appear to have slowed DKD progression rate but have been unable to substantially decrease the annual incidence of new cases of DKD related ESKD. Thus, new treatment targets are needed. Higher levels of serum uric acid (SUA) have been associated with increased risk and progression of DKD in persons with types 1 (T1D) and 2 (T2D) diabetes and of chronic kidney disease (CKD) in general. This review presents the epidemiological, clinical, and clinical trial evidence regarding the hypothesis that SUA reduction could slow progression of DKD and/or CKD in general.